Novo Nordisk: EPS growth of 17% in H1
(CercleFinance.com) - For H1 2024, Novo Nordisk reports EPS growth of 17% to DKK 10.
17 (approx. E1.36) and operating profit up 18% to almost 57.8bn DKK (+19% excluding currency effects).
At 133.4bn DKK, the Danish pharmaceutical company's sales rose by 24% (+25% excluding currency effects), including growth of 36% in North America and 9% in its international activities.
This growth is driven by increased demand for our GLP-1-based diabetes and obesity treatments, and we continue to reach more patients with our innovative treatments, management said.
For FY 2024, Novo Nordisk now expects 20%-28% growth at constant exchange rates for operating profit and 22%-28% for sales, compared with previous target ranges of 22%-30% and 19%-27% respectively.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
17 (approx. E1.36) and operating profit up 18% to almost 57.8bn DKK (+19% excluding currency effects).
At 133.4bn DKK, the Danish pharmaceutical company's sales rose by 24% (+25% excluding currency effects), including growth of 36% in North America and 9% in its international activities.
This growth is driven by increased demand for our GLP-1-based diabetes and obesity treatments, and we continue to reach more patients with our innovative treatments, management said.
For FY 2024, Novo Nordisk now expects 20%-28% growth at constant exchange rates for operating profit and 22%-28% for sales, compared with previous target ranges of 22%-30% and 19%-27% respectively.
Copyright (c) 2024 CercleFinance.com. All rights reserved.